Matches in Ubergraph for { <https://frink.apps.renci.org/.well-known/genid/B8d9a88b0f68179932d1e4d1c7e6e5ece> ?p ?o ?g. }
Showing items 1 to 5 of
5
with 100 items per page.
- B8d9a88b0f68179932d1e4d1c7e6e5ece NCIT_P378 "NCI" @default.
- B8d9a88b0f68179932d1e4d1c7e6e5ece type Axiom @default.
- B8d9a88b0f68179932d1e4d1c7e6e5ece annotatedProperty IAO_0000115 @default.
- B8d9a88b0f68179932d1e4d1c7e6e5ece annotatedSource NCIT_C180535 @default.
- B8d9a88b0f68179932d1e4d1c7e6e5ece annotatedTarget "An orally available selective inhibitor of the epidermal growth factor receptor (EGFR) mutant form T790M, with potential antineoplastic activity. Upon administration, alflutinib specifically binds to and inhibits the tyrosine kinase activity of EGFR T790M, a secondarily acquired resistance mutation. This prevents EGFR T790M-mediated signaling and leads to cell death in EGFR T790M-expressing tumor cells. EGFR, a receptor tyrosine kinase that is mutated in many tumor cell types, plays a key role in tumor cell proliferation and tumor vascularization. Compared to some other EGFR inhibitors, alflutinib may have therapeutic benefits in tumors with T790M-mediated drug resistance." @default.